Study of Alwextin® Cream in Treating Epidermolysis Bullosa
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how safe and effective allantoin 3% cream
(Alwextin) is in improving the healing of recurrent skin lesions and reducing overall
blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically
to the entire body once daily.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborator:
Ann & Robert H Lurie Children's Hospital of Chicago